Investor Confidence is Rising for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)

Investor Confidence is Rising for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)


The Brainstorm Cell Therapeutics Inc. (BCLI) shares are trading at higher $11.72 and the avg recommendation for the stock is Moderate Buy. The current analyst price target stands at $13.50.

To add more color to this target, the company’s high over the last year is $10.93 and the low is $3.43. Over the last 52 weeks, BCLI is up 7.23% while the S&P 500 is up 1.07%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, BCLI reported a profit of $0.19 million. Brainstorm Cell Therapeutics Inc. also saw revenues increase to $8.31 million. In addition, BCLI has free cash flow of -$15.04 million as of 03-2020 The company’s EBITDA came in at -$8.26 million which compares well with its peers.

BCLI Return on Equity (ROE) is 726.40%, and its Return on Assets is -255.20%. All told, it is clear that, BCLI needs to be on your watchlist.

Find out when BCLI reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. BCLI has a short ratio of 5.46 and outstanding shares of 28.42M.

Company Outlook

BCLI has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.81 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.10. Brainstorm Cell Therapeutics Inc. BCLI also noted assets of $18.07 million at the end of the last quarter. Investors should also keep an eye on sector updates as BCLI has historically followed its peers on positive news.

All told, Brainstorm Cell Therapeutics Inc. BCLI has strung together solid data and demonstrated underlying fundamentals. At its current valuation, BCLI represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Brainstorm Cell Therapeutics Inc. BCLI is now commanding a market cap of 330.15M and a float of 22.97M. BCLI is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of BCLI stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in BCLI, either long or short, and we have not been compensated for this article.